Here, we sought to demonstrate that mesothelin-bound SS-TR3 is phenotypically equivalent to membrane-anchored native TRAIL, thereby providing a link between targeted cancer drug development and native TRAIL biology. The gene discussed is TNFSF10; the disease is cancer.